CRO Novotech signs MOU with South Korean medical center

By Melissa Fassbender contact

- Last updated on GMT

Novotech is an Australia-based CRO operating in the Asia Pacific region. (Image: iStock/Gil-Design)
Novotech is an Australia-based CRO operating in the Asia Pacific region. (Image: iStock/Gil-Design)

Related tags: Contract research organization, Clinical trial

Novotech will conduct clinical trials at the 2,700-bed center with support from the medical’s center staff.

The Memorandum of Understanding (MOU) formalizes the company’s relationship with the Asan Medical Center's (AMC) Clinical Trial Center and its principal investigators.

The contract research organization (CRO) will help augment AMC’s clinical research capabilities internationally, and in turn, the center will provide professional and medical advice to Novotech for clinical trials conducted at the facility, including feasibility, principal investigator selection, and patient recruitment.

Novotech CEO Dr. John Moller told us the company has worked with AMC since it opened its Korea operation in 2008.

Novotech's CEO, Dr. John Moller, and the AMC’s Director of Asan Medical Center’s Clinical Trial Center, Dr. Young Suk Lim. (Image: Novotech)

"Novotech will work closely with the ASAN to ensure that we have early discussions with the Clinical Trial Centre and Key Opinion Leaders about projects that may be appropriate to Korea​," he said.

"The MOU also means that the most senior individuals in each organization will have closer direct access to one another and the two organizations will work to ensure rapid engagement and high priority start-up of new projects​," Moller added.

Dr. Young Suk Lim, director of the South Korea-based medical institution, commented that the AMC is committed to “increasing and expanding​” its medical and technology infrastructure.

As Outsourcing-Pharma.com previously reported​, the CRO market in Asia is expected to grow significantly through 2020.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us


View more